Profile data is unavailable for this security.
About the company
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its pipeline includes three clinical-stage development programs: TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity and other metabolic diseases. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic stability and liver distribution. It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.
- Revenue in USD (TTM)0.00
- Net income in USD-95.90m
- Incorporated2020
- Employees66.00
- LocationTerns Pharmaceuticals Inc1065 East Hillsdale Blvd.Suite 100, Suite 100FOSTER CITY 94404United StatesUSA
- Phone+1 (650) 525-5535
- Fax+1 (650) 275-4395
- Websitehttps://ternspharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Olema Pharmaceuticals Inc | 0.00 | -109.63m | 778.82m | 80.00 | -- | 3.43 | -- | -- | -2.06 | -2.06 | 0.00 | 3.97 | 0.00 | -- | -- | 0.00 | -50.73 | -30.06 | -56.10 | -31.40 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.76 | -- | -- | -- |
Arbutus Biopharma Corp | 10.06m | -77.09m | 781.56m | 73.00 | -- | 6.38 | -- | 77.68 | -0.4416 | -0.4416 | 0.0575 | 0.6488 | 0.0597 | -- | 4.59 | 137,821.90 | -45.77 | -52.62 | -53.21 | -58.11 | -- | -- | -766.20 | -537.81 | -- | -- | 0.00 | -- | -53.51 | 25.00 | -4.89 | -- | -2.40 | -- |
ORIC Pharmaceuticals Inc | 0.00 | -110.78m | 787.25m | 107.00 | -- | 2.50 | -- | -- | -1.76 | -1.76 | 0.00 | 4.47 | 0.00 | -- | -- | 0.00 | -35.69 | -33.92 | -37.77 | -35.77 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.99 | -- | 10.09 | -- |
Stoke Therapeutics Inc | 15.16m | -103.57m | 797.09m | 110.00 | -- | 3.26 | -- | 52.59 | -2.18 | -2.18 | 0.317 | 4.64 | 0.0537 | -- | 68.74 | 137,790.90 | -36.68 | -31.62 | -41.57 | -33.92 | -- | -- | -683.31 | -1,775.50 | -- | -- | 0.00 | -- | -29.22 | -- | -3.59 | -- | 11.56 | -- |
AbCellera Biologics Inc | 33.06m | -153.30m | 807.38m | 586.00 | -- | 0.7267 | -- | 24.43 | -0.5254 | -0.5254 | 0.1133 | 3.77 | 0.0224 | -- | 0.808 | 56,407.85 | -10.39 | 6.08 | -11.11 | 6.67 | -- | -- | -463.77 | 24.69 | -- | -- | 0.00 | 0.00 | -92.17 | 33.91 | -192.35 | -- | 70.96 | -- |
Arrivent Biopharma Inc | 0.00 | -74.89m | 812.78m | 40.00 | -- | 2.73 | -- | -- | -2.46 | -2.46 | 0.00 | 8.85 | 0.00 | -- | -- | 0.00 | -29.50 | -- | -31.02 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -87.86 | -- | -- | -- |
Dianthus Therapeutics Inc | 4.12m | -56.68m | 824.86m | 53.00 | -- | 2.30 | -- | 200.31 | -5.54 | -5.54 | 0.2092 | 12.20 | 0.0184 | -- | -- | 77,698.11 | -25.33 | -41.40 | -26.15 | -44.70 | -- | -- | -1,376.42 | -12,132.27 | -- | -- | 0.00 | -- | -- | -- | 43.04 | -- | -57.21 | -- |
Erasca Inc | 0.00 | -158.28m | 839.04m | 126.00 | -- | 1.80 | -- | -- | -0.9207 | -0.9207 | 0.00 | 1.65 | 0.00 | -- | -- | 0.00 | -32.76 | -- | -34.48 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 48.50 | -- | -- | -- |
Terns Pharmaceuticals Inc | 0.00 | -95.90m | 847.37m | 66.00 | -- | 3.23 | -- | -- | -1.31 | -1.31 | 0.00 | 3.11 | 0.00 | -- | -- | 0.00 | -36.84 | -41.34 | -38.72 | -45.70 | -- | -- | -- | -31,010.30 | -- | -- | 0.00 | -- | -- | -- | -49.49 | -- | -26.60 | -- |
Silence Therapeutics plc | 23.78m | -53.27m | 854.34m | 115.00 | -- | 5.62 | -- | 35.93 | -0.4282 | -0.4282 | 0.1899 | 1.06 | 0.1273 | -- | 2.56 | 206,778.60 | -28.51 | -43.60 | -32.89 | -54.91 | 56.40 | -- | -224.01 | -287.30 | -- | -- | 0.0016 | -- | 44.99 | -- | -6.86 | -- | 156.10 | -- |
Oruka Therapeutics Inc | 0.00 | -7.20m | 868.66m | 4.00 | -- | 0.9211 | -- | -- | -5.97 | -5.97 | 0.00 | 26.94 | 0.00 | -- | -- | 0.00 | -19.22 | -27.78 | -19.99 | -29.38 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 46.21 | -- | -- | -- |
89bio Inc | 0.00 | -174.61m | 877.99m | 70.00 | -- | 1.69 | -- | -- | -1.97 | -1.97 | 0.00 | 4.91 | 0.00 | -- | -- | 0.00 | -32.50 | -45.50 | -34.68 | -49.31 | -- | -- | -- | -- | -- | -- | 0.0465 | -- | -- | -- | -39.37 | -- | -36.58 | -- |
Tango Therapeutics Inc | 42.51m | -116.49m | 901.09m | 140.00 | -- | 3.63 | -- | 21.20 | -1.11 | -1.11 | 0.4068 | 2.31 | 0.1118 | -- | -- | 303,635.70 | -30.62 | -- | -35.13 | -- | -- | -- | -274.04 | -- | -- | -- | 0.00 | -- | 46.93 | -- | 5.95 | -- | -- | -- |
Perspective Therapeutics Inc | -1.87m | -49.02m | 908.25m | 116.00 | -- | 2.66 | -- | -- | -1.39 | -1.75 | -0.0437 | 5.06 | -0.0074 | -- | -- | -16,086.21 | -19.37 | -- | -20.14 | -- | -- | -- | -- | -- | -- | -- | 0.005 | -- | -- | -- | -- | -- | -- | -- |
MiMedx Group Inc | 340.46m | 89.67m | 914.62m | 895.00 | 12.47 | 5.44 | 9.32 | 2.69 | 0.4996 | 0.4622 | 2.08 | 1.15 | 1.67 | 2.70 | 6.69 | 380,402.30 | 48.16 | -4.14 | 60.79 | -5.90 | 83.41 | 83.61 | 28.76 | -2.70 | 3.22 | 13.06 | 0.1028 | -- | 20.03 | -2.19 | 310.29 | -- | -26.47 | -- |
Holder | Shares | % Held |
---|---|---|
Deep Track Capital LPas of 30 Jun 2024 | 6.10m | 8.67% |
Soleus Capital Management LP (Investment Management)as of 30 Jun 2024 | 4.95m | 7.03% |
BlackRock Fund Advisorsas of 30 Jun 2024 | 3.71m | 5.28% |
Citadel Advisors LLCas of 10 Jul 2024 | 3.29m | 4.67% |
Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 2.77m | 3.93% |
Point72 Asset Management LPas of 30 Jun 2024 | 2.69m | 3.82% |
Schonfeld Strategic Advisors LLCas of 30 Jun 2024 | 2.27m | 3.22% |
The Vanguard Group, Inc.as of 30 Jun 2024 | 2.26m | 3.21% |
Octagon Capital Advisors LPas of 30 Jun 2024 | 1.36m | 1.94% |
SSgA Funds Management, Inc.as of 30 Jun 2024 | 1.18m | 1.67% |